v3.20.2
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Income Statement [Abstract]        
Revenue
Operating expenses:        
General and administrative 2,909 1,724 8,474 5,331
Research and development 2,619 1,520 7,321 4,376
Total operating expenses 5,528 3,244 15,795 9,707
Loss from operations (5,528) (3,244) (15,795) (9,707)
Other income (expense):        
Interest expense (53)
Change in fair value - Senior Secured Convertible Notes and Senior Convertible Note 367 379 (5,521) (341)
Offering costs - Senior Secured Convertible Note and Senior Convertible Note (50) (660)
Debt extinguishments loss - Senior Secured Convertible Notes (663) (407) (4,600) (666)
Other income (expense), net (346) (28) (10,834) (1,007)
Loss before provision for income tax (5,874) (3,271) (26,629) (10,714)
Provision for income taxes
Net loss before noncontrolling interests (5,874) (3,271) (26,629) (10,714)
Net loss attributable to the noncontrolling interests 391 186 1,093 501
Net loss attributable to PAVmed Inc. (5,483) (3,085) (25,536) (10,213)
Less: Series B Convertible Preferred Stock dividends earned (74) (68) (215) (201)
Net loss attributable to PAVmed Inc. common stockholders $ (5,557) $ (3,153) $ (25,751) $ (10,414)
Per share information:        
Net loss per share attributable to PAVmed Inc. - basic and diluted $ (0.11) $ (0.10) $ (0.56) $ (0.35)
Net loss per share attributable to PAVmed Inc. common stockholders - basic and diluted $ (0.11) $ (0.10) $ (0.57) $ (0.36)
Weighted average common shares outstanding, basic and diluted 48,380,677 31,030,929 45,563,961 29,211,694

Source